Ovarian Cancer Breakthrough: Two Drugs Show Significant Survival Benefits
In a major advancement for ovarian cancer treatment, two new studies have unveiled promising therapies that could extend the lives of patients with a particularly aggressive form of the disease. The research, presented at the SGO 2026 annual meeting on women's cancer and published in The Lancet, highlights the potential of repurposing existing drugs to combat platinum-resistant ovarian cancer.
Relacorilant Offers New Hope
The first study focused on relacorilant, a pill currently used to treat Cushing's syndrome and other cancers. Researchers examined data from 381 patients with platinum-resistant ovarian cancer, a condition where the disease progresses within six months of platinum-based chemotherapy, typically leaving patients with an average survival of just one year post-diagnosis.
Patients who received relacorilant in addition to standard care lived an average of 16 months, compared to 11.9 months for those on usual care alone. This represents a 4.1-month improvement in median overall survival. Moreover, the study found that those taking relacorilant were 35% less likely to die from any cause.
The authors concluded that these outcomes position relacorilant combined with nab-paclitaxel as a new standard treatment option for this patient group.
Immunotherapy Enhances Survival Odds
A separate study, also presented at the SGO 2026 meeting and published in The Lancet, investigated the immunotherapy drug pembrolizumab. This treatment works by stimulating the body's immune system to target and destroy cancer cells.
Analyzing data from 643 women with platinum-resistant ovarian cancer, researchers discovered that patients who took pembrolizumab alongside usual care survived for an average of 17.7 months. In contrast, those receiving standard care alone lived for about 14 months on average.
The research team emphasized that these findings support pembrolizumab as part of a new standard of care regimen, offering a significant boost in survival time for affected women.
Understanding Ovarian Cancer
Ovarian cancer involves the uncontrolled growth of abnormal cells in the ovary, fallopian tube, or peritoneum, leading to tumor formation. It primarily affects women over 50 but can occur in anyone with ovaries. Early symptoms are often subtle and easily overlooked, including:
- Persistent bloating or a swollen abdomen
- Pelvic or abdominal pain
- Feeling full quickly after eating
- Increased urgency or frequency of urination
Other potential symptoms encompass indigestion, constipation, diarrhea, back pain, fatigue, unexplained weight loss, and unusual vaginal bleeding. The NHS advises consulting a GP if symptoms persist, worsen, or become more frequent, as early detection can significantly improve treatment outcomes.
These breakthroughs underscore the importance of ongoing research and innovation in oncology, providing renewed hope for patients facing this challenging diagnosis.
